ARTES attends BioEurope Spring 2019

Meet us at the Bio-Europe Spring 2018 tak­ing place in Vien­na, Aus­tria March 25 ‑27. Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine products.

SplitCore – the latest milestone in ARTES´ vaccine development offer

ARTES Biotech­nol­o­gy announces the acqui­si­tion of the unique Split­Core tech­nol­o­gy devel­oped by sci­en­tists at the Uni­ver­si­ty of Freiburg, Germany.

ARTES and Minapharm joint forces

ARTES Biotech­nol­o­gy GmbH, Ger­many, and Minapharm Phar­ma­ceu­ti­cals and Chem­i­cal Indus­tries S.A.E., Egypt, joint­ly announced today the for­ma­tion of a new strate­gic busi­ness pact, offer­ing pack­et solu­tion for bio­phar­ma­ceu­ti­cal processes .


Aim of this new strate­gic busi­ness coop­er­a­tion is to joint­ly out-license com­bi­na­tions of ARTES’ and Minapharm’s respec­tive pro­pri­etary tech­nolo­gies and prod­ucts to third par­ties world­wide. Both part­ners own and con­trol tech­nolo­gies for micro­bial and mam­malian recom­bi­nant cell lines, process­es and products.

The already exist­ing and estab­lished part­ner­ship among the com­pa­nies bases on a suc­cess­ful, long last­ing busi­ness rela­tion­ship. In this, ARTES acts as spe­cial­ist for micro­bial cell line and process devel­op­ment for recom­bi­nant pro­teins and Minapharm on the oth­er hand is the major play­er for pro­duc­tion and mar­ket­ing of bio-phar­ma­ceu­ti­cals in the MENA region.

With the com­bi­na­tion of ARTES’ and Minapharm’s busi­ness intel­li­gence and ser­vice solu­tions future clients will ben­e­fit from our lat­est, inno­v­a­tive devel­op­ments ”, Dr. Michael Pio­ntek, Man­ag­ing direc­tor of ARTES stat­ed, “and will get robust, proven man­u­fac­tur­ing expe­ri­ence and prod­uct reg­is­tra­tion.” Proven safe­ty and effi­ca­cy of prod­ucts will team up with high yield and low cost man­u­fac­tur­ing technology.

The estab­lished alliance with ARTES con­tin­u­ous­ly con­firms Minapharm’s posi­tion as a region­al biotech leader. Our emer­gence as such con­tributes to a rad­i­cal shift in both inno­va­tion and afford­abil­i­ty of bio­phar­ma­ceu­ti­cals as a func­tion of time. We have been able to demon­strate the via­bil­i­ty of our strat­e­gy to offer patients in the devel­op­ing world with a time­ly ben­e­fit of nov­el ther­a­peu­tic pro­teins. Our bio­phar­ma­ceu­ti­cal pipeline port­fo­lio reflects great poten­tial to expand our strat­e­gy and offers solu­tions for the man­age­ment of med­ical emer­gen­cies. We are glad that ARTES is shar­ing our vision” said Frank Mueller, Senior Man­ag­er Bio­phar­ma­ceu­ti­cal Projects of Minapharm.

ARTES successfully completed EU funded project Plurivax

ARTES Biotech­nol­o­gy explored very effec­tive in a SME con­sor­tium vac­cine devel­op­ments for vet­eri­nary applications.
Under the titel: “ERA-Net EuroTransBio‑8: PLURIVAX, devel­op­ment of a virus-like-par­ti­cle (VLP) based vac­cine plat­form and sta­ble for­mu­la­tion espe­cial­ly suit­ed for the vet­eri­nary appli­ca­tions, the EU coop­er­a­tion was part of the 8th Euro­Trans­Bio call and was fund­ed in the time peri­od from June 2014 to Novem­ber 2017 by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) and the Flan­ders (Bel­gium) agency for Inno­va­tion by Sci­ence and Tech­nol­o­gy (IWT).
For the devel­op­ment of vac­cines for human appli­ca­tions it is state of the art to use virus-like par­ti­cles (VLPs) as a vehi­cle. The use of these par­ti­cles has the advan­tage that they as such not being infec­tious but that they trans­port for­eign anti­gens in an ide­al way to the immune sys­tem. These very effec­tive and sim­ple mech­a­nism was the back­bone of the PLURIVAX project.
“As ini­tial nucle­us our pro­pri­etary VLP plat­form METAVAX® was tak­en. This plat­form has already been applied to the devel­op­ment of adju­vant-free vac­cine can­di­dates against dif­fer­ent human relat­ing dis­eases like flu, malar­ia and HIV”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “Our expres­sion host, the methy­lotroph­ic yeast Hansenu­la poly­mor­pha, is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for mass vac­ci­na­tions. Com­bi­na­tion of our both plat­forms build an excel­lent approach to low-cost mass pro­duc­tion of safe and effec­tive vaccines.”
ARTES chose eight dif­fer­ent, large mol­e­c­u­lar weight anti­gens derived from four animal‑ infect­ing virus­es. The bovine viral diar­rhea virus (BVDV) as an impor­tant pathogen of cat­tle, also infect­ing sheep and pigs. The clas­si­cal swine fever virus (CSFV), which is acknowl­edged as a glob­al threat for swine and is list­ed as noti­fi­able ani­mal dis­eases by the World Orga­ni­za­tion for Ani­mal Health. The feline leukemia virus (FeLV) as a retro­virus threat­en­ing domes­tic cats and the west nile virus (WNV) which is a mos­qui­to vec­tor trans­mit­ted zoonot­ic virus of the Fla­viviri­dae fam­i­ly. WNV cir­cu­lates in birds as nat­ur­al hosts but can be trans­mit­ted to mam­mals includ­ing humans caus­ing west nile fever.
First results were released in a sci­en­tif­ic paper under the title “Estab­lish­ment of a yeast-based VLP plat­form for anti­gen pre­sen­ta­tion” (Wet­zel et al. Microb Cell Fact (2018) 17:17 )
and more infor­ma­tion could be get on‑0868‑0

Future steps are, that in close dis­cus­sions with glob­al vet­eri­nary vac­cine man­u­fac­tur­er, ARTES’ explores the com­mer­cial appli­ca­tion of the results and of the plat­form in general.

ARTES attends Bio-Europe Spring 2018

Meet us at the Bio-Europe Spring 2018 tak­ing place in Ams­ter­dam March 12 ‑14. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing pre­sent­ing ARTES’ inno­v­a­tive range of cell line and process devel­op­ment solu­tions for bio-phar­ma­ceu­ti­cal and vac­cine prod­ucts. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES brings new vaccine advances to veterinary ‘Dragons’ Den’

ARTES will attend February’s Euro­pean Ani­mal Health Invest­ment Forum in Lon­don and will present its inno­v­a­tive tech­nolo­gies to poten­tial partners 
This will be ARTES’ sec­ond par­tic­i­pa­tion in the high pres­tige invest­ment net­work­ing event, which is seen as the ‘Drag­ons’ Den’ of vet­eri­nary medicine.
ARTES Man­ag­ing Direc­tor, Dr. Michael Pio­ntek, will use the forum to talk with inter­est­ed par­ties about lat­est devel­op­ments of the laboratory’s inno­v­a­tive pro­pri­etary vac­cine devel­op­ment plat­form, METAVAX®, which received a new EU-based grant of patent last August.
Meet us at the Euro­pean Ani­mal Health Invest­ment Forum tak­ing place in Lon­don, Feb­ru­ary 20 ‑21. Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES attends Biofit 2017

Meet us at the Biofit 2017 tak­ing place in Stras­bourg Novem­ber 28 ‑29. Michael Pio­ntek, Man­ag­ing Direc­tor at ARTES, will be present in the One-on-One Part­ner­ing and we are present with our own booth (num­ber F2). Con­tact us pre­vi­ous­ly for orga­niz­ing a per­son­al meet­ing or drop us a notice via the part­ner­ing sys­tem. We look for­ward to meet­ing you!

ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotech­nol­o­gy GmbH today announced that it has just obtained gov­ern­men­tal approval for ‘Crédit d’Im­pôt Recherche’ (CIR) for a three-year peri­od from the French Min­istry of High­er Edu­ca­tion and Research (MESR).

The French R&D tax cred­it CIR gives French com­pa­nies the abil­i­ty to claim tax relief on 30% on all gen­er­at­ed costs out­sourced to ARTES’ R&D services.
“We are pleased to receive this accred­i­ta­tion and to be approved as valid and reli­able R&D provider from the French Min­istry”, Dr Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES. “It allows our cus­tomers in France to ben­e­fit from tax relief of their R&D expens­es com­mit­ted to us and it will help us to tie up our rela­tion­ships with our present clients in France and to install new collaborations”.

ARTES Biotech­nol­o­gy is glob­al­ly active as R&D com­pa­ny spe­cial­ized in devel­op­ing bio­phar­ma­ceu­ti­cal and vac­cine pro­duc­tion processes.
The com­pa­ny oper­ates world­wide from its 850 m² S1 facil­i­ties in Lan­gen­feld, from where it also offers cell line engi­neer­ing based on yeast (Hansenu­la poly­mor­pha) and bac­te­r­i­al (E. coli and Bacil­lus) expres­sion plat­forms, lab scale up- and down­stream process devel­op­ment, sup­ply of non-GMP bulk mate­r­i­al (API) for activ­i­ty and tox­i­c­i­ty tests and tech­nol­o­gy trans­fer to cGMP facil­i­ties and scale-up support.

ARTES was part of a successful international consortium

EU Research Project Nano3Bio sums up:
Promis­ing achieve­ments for win­ning future raw materials

Since fos­sil raw mate­ri­als are rapid­ly run­ning out, their sub­sti­tu­tion by renew­able resources is becom­ing increas­ing­ly impor­tant. In this process, the bio­log­i­cal pro­duc­tion of raw mate­ri­als will have to play a lead­ing role. The inter­na­tion­al project Nano3Bio, includ­ing ARTES Biotech­nol­o­gy has con­tributed to mas­ter this chal­lenge. Nano3Bio’s main goal was the biotech­no­log­i­cal pro­duc­tion of so-called chi­tosans, which can be used as raw mate­ri­als for med­i­cine, agri­cul­ture, cos­met­ics and oth­er appli­ca­tion fields. The Euro­pean Com­mis­sion sup­port­ed the research project with almost nine mil­lion Euros over the past four years. Recent­ly, the con­sor­tium held its final con­fer­ence ‘The Future of Chi­tosans’ in Hyder­abad, India.
“We’re proud of Nano3Bio’s out­comes. In impor­tant fields, the con­sor­tium achieved or pre­pared break­throughs from basic research to biotech­no­log­i­cal appli­ca­tions”, says Pro­fes­sor Dr. Bruno Moer­schbach­er, biol­o­gist at the Uni­ver­si­ty of Mün­ster and coor­di­na­tor of the project.

More about Nano3Bio and on the future of chi­tosans:

ARTES received next grant of patent for METAVAX®

ARTES is pleased to announce a new EU based grant of patent for their well-proven virus-like-par­ti­cle (VLP) tech­nol­o­gy plat­form METAVAX®. 

The new patent inte­grates exact­ly in our exist­ing patent port­fo­lio and will fur­ther strength­en our tech­nol­o­gy offer”, said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES. “In com­bi­na­tion with our pro­pri­etary yeast expres­sion tech­nol­o­gy our anti­gen pre­sen­ta­tion plat­form METAVAX® is an excel­lent and unique tool for the devel­op­ment of effec­tive, safe and afford­able vaccines.”

Cur­rent­ly, the plat­form METAVAX® is used in sev­er­al clients’ projects as well as in sev­er­al in-house research projects. With­in the “Pluri­vax” project, fund­ed by the Ger­man Fed­er­al Min­istry of Edu­ca­tion and Research (BMBF) as part of the 8th Euro­Trans­Bio call, ARTES enhances its VLP based vac­cine plat­form METAVAX® and devel­ops process­es espe­cial­ly suit­ed for the vet­eri­nary applications.

Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. With this new patent, we have addi­tion­al rein­force­ment to our exist­ing patent estate,” said Dr. Melanie Piontek.